Debt, Equity Deals for Pathogenetix

11/5/10Follow @xconomy

Woburn, MA-based biotech Pathogenetix, formerly known as U.S. Genomics, has raised $1.3 million in equity-based funding, and $900,000 of a planned $1.2 million debt-based offering, according to filings with the SEC. U.S. Genomics developed biodefense and diagnostic technologies, and raised $4.5 million in private equity funding from Becton, Dickinson & Co in 2008, as part of a strategic partnership for pursuing diagnostics for infectious diseases. Pathogenetix has not yet returned a call seeking comment on the newest funding and the company name change.

By posting a comment, you agree to our terms and conditions.